Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03668951 · ClinicalTrials.gov registry record · Phase 1

Pharmacokinetic Study of Dexmedetomidine After Intra-Nasal and Buccal Dosing in Children

A Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.

Completed
Registry status
Phase 1
Development phase
18
Enrollment target

NCT03668951 is a Phase 1 study that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 18 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03668951, a Phase 1 study, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target

Study Summary

This research study is a continuation of a previous DEX PK study. It is examining the absorption of Dexmedetomidine (DEX) in the blood when given orally and as a nasal spray. This study will help us determine the best dosing amount for children undergoing sedation or anesthesia with DEX.

Interventions

  • DRUG Dexmedetomidine buccal
  • DRUG Dexmedetomidine Intranasal

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2018-08-20
Est. Completion 2022-05-03
Phase Phase 1

What the Registry Record Tells You About NCT03668951

The ClinicalTrials.gov registry entry for NCT03668951 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Dexmedetomidine buccal is the first listed.

NCT03668951 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03668951 about?

NCT03668951 is a clinical study titled "Pharmacokinetic Study of Dexmedetomidine After Intra-Nasal and Buccal Dosing in Children". This research study is a continuation of a previous DEX PK study. It is examining the absorption of Dexmedetomidine (DEX) in the blood when given orally and as a nasal spray. This study will help us determine the best dosing amount for children undergoing sedation or anesthesia with DEX.

What is the current status of trial NCT03668951?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-08-20. Estimated completion is 2022-05-03.

What interventions are being tested in trial NCT03668951?

The interventions under investigation include: Dexmedetomidine buccal (DRUG), Dexmedetomidine Intranasal (DRUG).

Who is sponsoring clinical trial NCT03668951?

This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.